Blocking the PD‐1 receptor, preventing binding and activation of PD‐L1 and PD‐L2; the inhibition of the PD‐1 pathway results in immune checkpoint enhancing T‐cell‐mediated immune response leading to T‐cell activation and proliferation against tumor cells. Here, PDCD1LG2 is linked to neoplasm.